China quietly became biotech’s back-office, from molecule synthesis and clinical trials to novel drug licensing. Now the industry—and Washington—are rethinking the risks.
Four drug companies — Agomab Therapeutics, Eikon Therapeutics, Spyglass Pharma, and Veradermics — went public this week, ...
The latest firm to top up its venture capital coffers is Austin, Texas-based Santé Ventures, which on Monday announced its ...
A spike in M&A activity and stock prices have pulled biotech out of a yearslong downturn. But regulatory tumult and fierce ...
The confluence of China’s rapidly rising biotech prowess and US policy decisions that hamper the industry is a cause for ...
Life sciences leaders in Boston are increasingly concerned that the "millionaires tax" is driving away founders and investors ...
Grogan served as assistant to President Trump and director of the Domestic Policy Council 2019-2020. On April 15, President Trump issued an awaited executive order on drug pricing, kicking off a new ...
If you look at a stock chart mapping the performance of the State Street SPDR S&P Biotech exchange-traded fund since early 2021, it seems to tell a simple story: The biotech sector has been a disaster ...
Opening up about drug pricing decisions is not optional for biopharma anymore. For the sake of credibility, companies should embrace it.
Department of Economic & Community Development Commissioner Daniel O'Keefe speaks at the BioCT legislative breakfast in New ...
The U.S. biotechnology market enters 2026 as the largest global biotech market, with an estimated size of $552.39 billion in 2023, and is projected to grow to $1.24 trillion by 2030.
T he biotech and pharmaceutical sectors stand at the brink of innovation and strategic transformation. Market momentum continues to build, with the global biotechnology market valued at around $2 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results